Mr. William Williams reports

BRIACELL THERAPEUTICS ANNOUNCES CLOSING OF OFFERING

Briacell Therapeutics Corp. has closed its best-efforts offering of 1,449,300 common shares. Each common share was sold at an offering price of $3.25 per share. All of the common shares in the offering were offered by the company. Total gross proceeds from the offering, before deducting placement agents' fees and other offering expenses, were approximately $4.7-million. The company relied upon the exemption set forth in Section 602.1 of the Toronto Stock Exchange company manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as the Nasdaq Stock Market.

The company intends to use the net proceeds from the offering for working capital requirements, general corporate purposes and the advancement of business objectives.

ThinkEquity acted as the sole placement agent for the offering.

About Briacell Therapeutics Corp.

Briacell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer.

We seek Safe Harbor.